Yuan Ping

Yuan Ping

Auto-generated profile, based on publicly available information

Yuan Ping

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
CLChongyi Liu
Chongyi Liu
TWTao Wan
Tao Wan
HWHui Wang
Hui Wang
SZSong Zhang
Song Zhang
YPYuan Ping
Yuan Ping
YCYiyun Cheng
Yiyun Cheng
We report the rational design of a polymer with unprecedented and robust efficiency for cytosolic delivery of native proteins.

16 September 2022 in Science Advances
Verified
Journal Article
Open access
TWTao Wan
Tao Wan
JZJiafeng Zhong
Jiafeng Zhong
QPQi Pan
Qi Pan
TZTianhua Zhou
Tianhua Zhou
YPYuan Ping
Yuan Ping
XLXiangrui Liu
Xiangrui Liu
CRISPR-Cas9 gene editing has emerged as a powerful therapeutic technology, but the lack of safe and efficient in vivo delivery systems, especially for tissue-specific vectors, limits its broad clinical applications. Delivery of Cas9 ribonucleoprotein (RNP) owns competitive advantages over other options; however, the large size of RNPs exceeds the loading capacity of currently available delivery vectors. Here, we report a previously unidentified genome editing delivery system, named exosome RNP , in which Cas9 RNPs were loaded into purified exosomes isolated from hepatic stellate cells through electroporation. Exosome RNP facilitated effective cytosolic delivery of RNP in vitro while specifically accumulated in the liver tissue in vivo. Exosome RNP showed vigorous therapeutic potential in acute liver injury, chronic liver fibrosis, and hepatocellular carcinoma mouse models via targeting p53 up-regulated modulator of apoptosis ( PUMA ), cyclin E1 ( CcnE1 ), and K (lysine) acetyltransferase 5 ( KAT5 ), respectively. The developed exosome RNP provides a feasible platform for precise and tissue-specific gene therapies of liver diseases.

5 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKexin Su
Kexin Su
LSLu Shi
Lu Shi
TSTao Sheng
Tao Sheng
XYXinxin Yan
Xinxin Yan
LLLixin Lin
Lixin Lin
SLShuai Liu
Shuai Liu
Fully targeted mRNA therapeutics necessitate simultaneous organ-specific accumulation and effective translation. Despite some progress, delivery systems are still unable to fully achieve this. Here, we reformulate lipid nanoparticles (LNPs) through adjustments in lipid material structures and compositions to systematically achieve the pulmonary and hepatic (respectively) targeted mRNA distribution and expression. A combinatorial library of degradable-core based ionizable cationic lipids is designed, following by optimisation of LNP compositions. Contrary to current LNP paradigms, our findings demonstrate that cholesterol and phospholipid are dispensable for LNP functionality. Specifically, cholesterol-removal addresses the persistent challenge of preventing nanoparticle accumulation in hepatic tissues. By modulating and simplifying intrinsic LNP components, concurrent mRNA accumulation and translation is achieved in the lung and liver, respectively. This targeting strategy is applicable to existing LNP systems with potential to expand the progress of precise mRNA therapy for diverse diseases.

20 December 2019 in Nano Letters
Verified
Journal Article
Closed access
QCQi Chen
Qi Chen
HBHongzhen Bai
Hongzhen Bai
WWWangteng Wu
Wangteng Wu
GHGuojun Huang
Guojun Huang
YLYang Li
Yang Li
YPYuan Ping
Yuan Ping

30 March 2015 in Nano Letters
Verified
Journal Article
Closed access
QHQinglian Hu
Qinglian Hu
MWMin Wu
Min Wu
CFChun Fang
Chun Fang
CCChangyong Cheng
Changyong Cheng
MZMengmeng Zhao
Mengmeng Zhao
GTGuiliang Tang
Guiliang Tang

12 March 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
TWTao Wan
Tao Wan
QPQi Pan
Qi Pan
YPYuan Ping
Yuan Ping
We report a dissolvable microneedle (MN) patch that can mediate transdermal codelivery of CRISPR-Cas9–based genome-editing agents and glucocorticoids for the effective treatment of inflammatory skin disorders (ISDs). The MN is loaded with polymer-encapsulated Cas9 ribonucleoprotein (RNP) targeting NLRP3 and dexamethasone (Dex)–containing polymeric nanoparticles. Upon insertion into the skin, the MN can be dissolved quickly to release two types of nanoformulations, which are subsequently internalized by keratinocytes and surrounding immune cells to exert their therapeutic effects in the inflammatory subcutaneous layers. Thus, the MN-enabled transdermal codelivery of Cas9 RNP nanocomplexes and Dex nanoparticles result in the disruption of subcutaneous intracellular NLRP3 inflammasomes, which is demonstrated to be critical to alleviate skin inflammations and contributes to glucocorticoid therapy in mouse models of ISDs, including psoriasis and atopic dermatitis. Our study offers innovative insights into the rational design of transdermal delivery systems and defines an effective therapeutic option for the treatment of ISDs.